Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome (GBS-PRAISING)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05114941
Recruitment Status : Not yet recruiting
First Posted : November 10, 2021
Last Update Posted : March 16, 2022
Sponsor:
Information provided by (Responsible Party):
Wang Miao, The First Affiliated Hospital of Zhengzhou University

Brief Summary:
Guillain-Barre syndrome is an immune-mediated acute inflammatory peripheral neuropathy. The currently effective treatment methods include intravenous immunoglobulin and plasma exchange. Immunoadsorption has been widely used to treat immune-related diseases. There are currently no prospective large-sample clinical trials of immunoadsorption therapy for Guillain-Barre syndrome. The neuro-intensive care unit of the First Affiliated Hospital of Zhengzhou University is preparing to carry out a prospective, multi-center, randomized parallel controlled clinical study on the efficacy and safety of protein A immunoadsorption and intravenous immunoglobulin (IVIG) in the treatment of Guillain-Barre syndrome. It is estimated that 204 patients with Guillain-Barre syndrome will be included. The patients will be randomly assigned to the immunoadsorption group and the IVIG group. The primary outcome measure: changes in Hughes scores (4 weeks after starting treatment vs. baseline (before starting treatment) ). This study aims to explore the efficacy and safety of protein A immunoadsorption and intravenous immunoglobulin in the treatment of Guillain-Barre syndrome.

Condition or disease Intervention/treatment Phase
Guillain-Barre Syndrome Device: immunosorbent column Drug: intravenous immunoglobulin Not Applicable

Detailed Description:

Guillain-Barre syndrome (GBS) is an immune-mediated acute inflammatory peripheral neuropathy. The currently proven effective treatment methods include intravenous immunoglobulin and plasma exchange. In the clinical treatment process, the plasma source is often stressed, forcing the treatment to be terminated. Intravenous immunoglobulin therapy may cause allergies. Based on the above reasons, immunosorbent technology came into being.

Immunoadsorption technology is widely used in clinical treatment of immune-related diseases. Protein A can recognize and bind to the Fc segment of human antibodies. The protein A immunosorbent column uses recombinant staphylococcal protein A as its ligand. The protein can specifically recognize and bind to the Fc segment of human antibodies, so it can adsorb human antibodies, mainly immunoglobulin G, and can adsorb immunoglobulin M and immunoglobulin A at the same time. The binding of protein A and antibody is reversible.

Immunoadsorption therapy has obvious advantages: The patient's own plasma is transfused without replacement fluid; It can prevent infection Diseases such as viral hepatitis, AIDS, etc.; The adsorption is selective or specific, and normal plasma components including coagulation factors, etc., only slightly decrease; Does not affect the simultaneous drug treatment; The protein A immunosorbent column can be reused; The treatment effect is better, and the amount of plasma purified by a single immunoadsorption is 1.5 to 3 times that of plasma exchange.

The First Affiliated Hospital of Zhengzhou University is preparing to carry out a prospective, multi-center, randomized parallel controlled clinical study on the effectiveness and safety of protein A immunoadsorption and intravenous immunoglobulin in the treatment of Guillain-Barre syndrome. The control group received intravenous immunoglobulin injections using the standard treatment recommended by the Guilan-Barre Syndrome Guidelines. Compare the effectiveness and safety of the two treatment regimens in the treatment of Guillain-Barre syndrome, and explore a more effective and safe treatment regimen for the treatment of Guillain-Barre syndrome.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 204 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Multi-center, Randomized Parallel Controlled Clinical Study on the Efficacy and Safety of Protein A Immunoadsorption and Intravenous Immunoglobulin in the Treatment of Guillain-Barre Syndrome
Estimated Study Start Date : September 1, 2022
Estimated Primary Completion Date : December 1, 2024
Estimated Study Completion Date : December 31, 2024


Arm Intervention/treatment
Experimental: Immunoadsorption group
Protein A immunoadsorption therapy
Device: immunosorbent column
Immunoadsorption treatment regimen: the treatment is performed once every 1-3 days, at least 5 times, and the amount of regenerated plasma for each treatment is 1 to 3 times the plasma volume. The immunosorbent column adopts the protein A immunosorbent column.
Other Name: Protein A Immunoadsorption

Active Comparator: intravenous immunoglobulin group
Treatment with intravenous immunoglobulin
Drug: intravenous immunoglobulin
Intravenous immunoglobulin treatment regimen: intravenous immunoglobulin therapy, 400mg/kg/d, once a day, for at least 5 consecutive days.




Primary Outcome Measures :
  1. Changes in Hughes scores [ Time Frame: 4 weeks after starting treatment vs. baseline (before starting treatment) ]
    Compared with the patient's Hughes score before treatment, the change of Hughes scores 4 weeks after the start of protein A immunoadsorption or intravenous immunoglobulin treatment.


Secondary Outcome Measures :
  1. Changes in Hughes scores [ Time Frame: 2 weeks after starting treatment vs. baseline (before starting treatment) ]
    Compared with the patient's Hughes score before treatment, the change of Hughes scores 2 weeks after the start of protein A immunoadsorption or intravenous immunoglobulin treatment.

  2. Reached Hughes Grade 2 [ Time Frame: From date of first treatment until the date of patient's recovery to Hughes Grade 2 or end date of clinical trial, whichever came first, assessed up to 4 weeks. ]
    The time from the start of treatment to the patient's recovery to Hughes Grade 2. The time from the start of protein A immunoadsorption or intravenous immunoglobulin treatment to the time the patient recovers to be able to walk independently for a distance of more than 5 meters.

  3. Ventilator application time [ Time Frame: For patients who require ventilator-assisted ventilation, from date of start use ventilator until participants leave the ventilator or end date of clinical trial, whichever came first, assessed up to 4 weeks. ]
    For patients with ventilator-assisted ventilation, the length of time from the beginning of treatment to leaving the ventilator.

  4. Total time in ICU [ Time Frame: From the date the patient enters the ICU until the patient leaves the ICU or the clinical trial ends, whichever came first, assessed up to 4 weeks. ]
    The total time that patients in the protein A immunoadsorption or intravenous immunoglobulin group were admitted to the ICU.

  5. Changes of total lymphocyte count, interleukin-6, interleukin-8, cerebrospinal fluid protein [ Time Frame: 2 weeks after starting treatment vs. baseline (before starting treatment) ]
    Compared with the results before treatment, changes of total lymphocyte count, interleukin-6, interleukin-8, cerebrospinal fluid protein after 2 weeks of the start of the treatment.

  6. Changes of Compound muscle action potential and motor nerve conduction velocity of bilateral tibial nerves [ Time Frame: 4 weeks after starting treatment vs. baseline (before starting treatment) ]
    Changes of Compound muscle action potential and motor nerve conduction velocity of bilateral tibial nerves before the treatment and 4 weeks after the start of the treatment in the protein A immunoadsorption or intravenous immunoglobulin group.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Meet the diagnostic criteria of Guillain - Barre syndrome;
  2. The onset is within 2 weeks;
  3. Age is greater than or equal to 18 years old and less than or equal to 60 years old;
  4. Hughes function classification is greater than or equal to 3;
  5. The subject or his legal representative can understand the purpose of the research, show sufficient compliance with the research protocol, and sign an informed consent form.

Exclusion Criteria:

  1. Those who are pregnant;
  2. Three months before the screening period, receive immunoadsorption therapy or intravenous immunoglobulin therapy;
  3. Those who have a history of allergies in the membrane of the plasma separator;
  4. Those who must use angiotensin-converting enzyme inhibitor drugs within 1 week before being included in the trial and during treatment and cannot be stopped;
  5. Severe active bleeding or diffuse intravascular coagulation, patients with systemic circulatory failure that are difficult to correct with drugs;
  6. Severe cardiac insufficiency, that is, those who have reached NYHA IV according to the heart failure classification standards of the New York Heart Association (NYHA);
  7. There are contraindications to intravenous immunoglobulin;
  8. Those with other system autoimmune diseases;
  9. Diagnosis of variant GBS: such as Miller-Fisher syndrome, GBS with cranial nerve damage, sensory GBS, pan-autonomous GBS. Patients with chronic inflammatory demyelinating polyperipheral neuropathy whose condition has been significantly alleviated when visiting a doctor;
  10. Subjects who have participated in any other drug or medical device clinical trials within 1 month before entering the screening period; Note: Subjects who participated in observational studies (that is, the study does not require changes or other interventions) will not be excluded;
  11. Patients who cannot obtain informed consent;
  12. Those who cannot receive active and comprehensive treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05114941


Contacts
Layout table for location contacts
Contact: Wang Miao, Prof 0086-13592567185 miaowang7211@126.com

Locations
Layout table for location information
China, Henan
First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450052
Contact: Wang Miao, Prof         
Principal Investigator: Wang Miao, Prof         
Sponsors and Collaborators
The First Affiliated Hospital of Zhengzhou University
Investigators
Layout table for investigator information
Study Director: Junfang Teng, Prof The First Affiliated Hospital of Zhengzhou University
Principal Investigator: Wang Miao, Prof The First Affiliated Hospital of Zhengzhou University
Layout table for additonal information
Responsible Party: Wang Miao, professor, The First Affiliated Hospital of Zhengzhou University
ClinicalTrials.gov Identifier: NCT05114941    
Other Study ID Numbers: 2021-KY-0709
First Posted: November 10, 2021    Key Record Dates
Last Update Posted: March 16, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: After the clinical trial is completed, the individual participant data will be shared with other researchers.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Available after five years, permanent.
Access Criteria: No.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Wang Miao, The First Affiliated Hospital of Zhengzhou University:
immunoadsorption
intravenous immunoglobulin
Additional relevant MeSH terms:
Layout table for MeSH terms
Guillain-Barre Syndrome
Syndrome
Disease
Pathologic Processes
Polyradiculoneuropathy
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Polyneuropathies
Autoimmune Diseases
Immune System Diseases
Immunoglobulins
Immunoglobulins, Intravenous
Antibodies
gamma-Globulins
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs